Related Experiment Video

Updated: Oct 9, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.9K

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Dimitri Poddighe1,2, Elena Kovzel2

  • 1Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan, 010000, Kazakhstan.

Journal of Inflammation Research
|December 22, 2021
PubMed

Insights

Patients on anti-type 2 biologics for chronic conditions did not experience worse COVID-19 outcomes. This treatment appears safe and may even offer protection against severe SARS-CoV-2 infection.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pulmonology

Background:

  • The COVID-19 pandemic significantly impacted chronic disease management, particularly respiratory and allergic disorders.
  • Concerns existed regarding the safety of immunosuppressive/immunomodulatory drugs during SARS-CoV-2 infection.

Purpose of the Study:

  • To review and analyze clinical evidence on COVID-19 outcomes in patients using anti-type 2 inflammation biologics.
  • To assess the safety and impact of these biologics on SARS-CoV-2 infection course and severity.

Main Methods:

  • Systematic review and analysis of existing clinical data.
  • Focus on patients treated with anti-IgE, anti-IL-5, and anti-IL-4 biological agents who contracted COVID-19.

Main Results:

  • Treatment with anti-Th2 biologics was generally safe in patients with COVID-19.
  • These therapies did not appear to worsen the clinical course or outcomes of COVID-19.
  • Evidence suggests a potential protective effect against severe forms of SARS-CoV-2 infection.

Conclusions:

  • Anti-type 2 biologics are safe for patients with chronic conditions who develop COVID-19.
  • These treatments do not increase susceptibility to SARS-CoV-2 infection.
  • Continuing anti-Th2 biologic therapy during the pandemic is advisable and may mitigate COVID-19 severity.
Keywords:
COVID-19SARS-CoV-2asthmabenralizumabbiologicschronic spontaneous urticariadupilumabmepolizumabomalizumabreslizumab

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.5K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
255
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
230
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
30
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
41
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
316
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
53